^
    4d
    Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies (clinicaltrials.gov)
    P1, N=42, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2029 | Trial primary completion date: Jan 2027 --> Jan 2028
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    CD30 biAb-AATC • Leukine (sargramostim)
    8d
    NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Mar 2026 --> Jun 2026
    Trial completion date
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    26d
    A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ENG (Endoglin)
    |
    HER-2 negative • PD-L1 negative
    |
    cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)
    26d
    PNeoVCA: Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=132, Recruiting, Mayo Clinic | N=36 --> 132 | Trial completion date: Feb 2026 --> Mar 2028 | Trial primary completion date: Feb 2025 --> Mar 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Leukine (sargramostim) • neoantigen peptide vaccine
    27d
    Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (clinicaltrials.gov)
    P2, N=60, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting
    Enrollment open
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    1m
    Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov)
    P3, N=1449, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    1m
    Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    cyclophosphamide • topotecan • Qarziba (dinutuximab beta) • iberdomide (CC-220) • Unituxin (dinutuximab) • Leukine (sargramostim)
    1m
    NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2025 --> Mar 2026
    Trial completion date
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    2ms
    Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov)
    P2, N=94, Active, not recruiting, Children's Oncology Group | Trial completion date: Apr 2026 --> Mar 2029
    Trial completion date
    |
    temozolomide • irinotecan • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    2ms
    Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov)
    P2, N=34, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    sunitinib • Recentin (cediranib) • Leukine (sargramostim) • Neupogen (filgrastim) • loperamide
    3ms
    A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov)
    P2/3, N=600, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar) • Leukine (sargramostim)
    4ms
    Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (clinicaltrials.gov)
    P2, N=60, Suspended, Roswell Park Cancer Institute | Not yet recruiting --> Suspended
    Trial suspension
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)